|
Volumn 10, Issue 4, 2013, Pages 259-263
|
Policy statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACT;
ARTICLE;
HEALTH CARE POLICY;
HUMAN;
LAW;
MEDICAL SOCIETY;
ONCOLOGY;
PHARMACOECONOMICS;
DRUG COST;
DRUG INDUSTRY;
ECONOMICS;
FEE;
LEGISLATION AND JURISPRUDENCE;
MEDICAID;
PROCEDURES;
UNITED STATES;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC AGENTS;
DRUG COSTS;
DRUG INDUSTRY;
HUMANS;
MEDICAID;
MEDICAL ONCOLOGY;
PRESCRIPTION FEES;
UNITED STATES;
|
EID: 84909584842
PISSN: 15547477
EISSN: 1935469X
Source Type: Journal
DOI: 10.1200/JOP.2014.001432 Document Type: Article |
Times cited : (12)
|
References (17)
|